Zapnometinib

Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC50 of 5.7 nM. Zapnometinib exhibits antiviral activity against influenza virus and antibacterial activities[1][2][3].

Product Specifications

CAS Number

[303175-44-2]

Product Name Alternative

PD0184264; ATR-002

UNSPSC

12352005

Hazard Statement

H302, H413

Target

Bacterial; Influenza Virus; MEK

Type

Reference compound

Related Pathways

Anti-infection; MAPK/ERK Pathway

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/zapnometinib.html

Purity

99.85

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

O=C(O)C1=CC=C(F)C(F)=C1NC2=CC=C(I)C=C2Cl

Molecular Formula

C13H7ClF2INO2

Molecular Weight

409.55

Precautions

H302, H413

References & Citations

[1]Laure M, et, al. Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model. Antiviral Res. 2020 Jun;178:104806.|[2]Hamza H, et, al. Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002. Front Microbiol. 2021 Feb 12;12:611958.|[3]Bruchhagen C, et, al. Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound. Sci Rep. 2018 Jun 14;8 (1) :9114.